Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271311 | 0.82 | NAPRT (0.49) | NAPRTTBXAS1KDM4ECHRNB2CHRNA4 | |
| SCHEMBL1271314 | 0.79 | CHRNB2 (0.50) | NAPRTTBXAS1CHRNB2CHRNA4CYP1A2 | |
| SCHEMBL12139973 | 0.79 | SMN1; SMN2 (0.46) | NAPRTTBXAS1CHRNB2CHRNA4CYP1A2 | |
| SCHEMBL27468836 | 0.79 | CYP1A2 (0.52) | NAPRTCHRNB2CHRNA4LMNACYP1A2 | |
| SCHEMBL18571274 | 0.78 | ALDH1A1 (0.49) | TBXAS1CHRNB2CHRNA4PKMKMT2A | |
| SCHEMBL5696687 | 0.78 | CHRNB2 (0.50) | NAPRTCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL14011299 | 0.78 | NAMPT (0.51) | TBXAS1CHRNB2CHRNA4LMNA | |
| SCHEMBL14011331 | 0.77 | ALDH1A1 (0.45) | TBXAS1CYP1A2CYP2D6 | |
| SCHEMBL3252117 | 0.77 | CA1 (0.52) | KMT2A | |
| SCHEMBL24425794 | 0.76 | ALDH1A1 (0.42) | TBXAS1KMT2ACYP1A2CYP2D6RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20130040998-A1 | FLUORINATED HDAC INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NAPRT 3455/4885TBXAS1 202/4885KDM4E 3761/4885 |
| US-20130040998-A1 | FLUORINATED HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | NAPRT 517/4885TBXAS1 4199/4885KDM4E 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.